Programmed cardiac myocyte death contributes to pathological ventricular remodeling and the progression of myocardial infarction or pressure overload hypertrophy to dilated cardiomyopathy. Recent work has identified importance of stress-mediated transcriptional induction of BNIP3 (BCL2 and 19-kDa interacting protein-3) and NIX/BNIP3L in cardiac remodeling. Here, the regulatory mechanisms for these two factors in the heart and their effects on programmed cardiomyocyte death are reviewed, with a focus on information derived from studies using mouse models of cardiac BNIP3 and NIX/BNIP3L overexpression and gene ablation.
Introduction
The goal of revitalizing dead tissue is almost as old as our ability to understand the differences between life and death. The biblical Lazarus miracle used the power of God to restore life. In Mary Shelley's Frankenstein, electricity provided the spark of life to the monster. Herbert West, a medical student in the HP Lovecraft's short story that was popularized in a series of the 1980s 'Re-Animator' horror movies, used chemical solutions to revitalize small animals and, eventually, the Dean of the medical school (with unfortunate consequences). Now, modern tools of genetic manipulation and an explosion in our understanding of the molecular processes that lead to cell death provide an opportunity not to bring dead tissue to life, but to interrupt intrinsic pathways leading to predetermined cell death. The promise of this approach is especially great in the heart, where tissue regeneration after injury does not occur to a meaningful extent. Here, we review recent developments delineating the functions of BNIP3 (BCL2 and 19-kDa interacting protein-3) and NIX/BNIP3L, two cell suicide genes that are induced in response to cardiac injury or stress, in development of heart failure, and describe the potential to prevent heart failure by interrupting BNIP3-and NIX/BNIP3L-mediated programmed cardiomyocyte death.
Primary or secondary cardiomyocyte loss and the path to heart failure Heart failure is a clinical syndrome defined as any condition where the rate of blood delivery to systemic tissues is insufficient to meet their metabolic needs. This definition includes situations where myocardial function is normal and cardiac output (the volume of blood pumped per unit of time, B5 l/min in humans) is within accepted parameters or increased, such as in profound anemia and arteriovenous communications (shunts). However, the overwhelming majority of clinical heart failure cases are the consequence of primary myocardial dysfunction, with depressed cardiac output. In North America and Europe, heart failure is largely attributable to ischemic or hypertensive cardiomyopathy, with genetic disorders, sleep apnea, viral, toxic and peripartum myocardial disease accounting for most other cases (Hunt et al., 2005) .
Primary myocardial dysfunction leading to heart failure can be temporary, as with alcoholic cardiomyopathy and post-ischemic myocardial 'stunning' (Bolli and Marban, 1999) . More commonly, however, heart failure is irreversible because it results from the physical loss of functioning cardiac myocytes, so-called 'cardiomyocyte dropout' (Diwan and Dorn, 2007) . In coronary atherosclerosis and ischemic heart disease, cardiomyocyte dropout tends to be focal, whereas it is more diffuse in nonischemic failure (Berry et al., 1993; Olivetti et al., 1997) . Importantly, the loss of functional contractile units of the heart and their replacement by fibrous scar or diffuse interstitial fibrosis produces secondary structural changes in the ventricles that increase the work required for ventricular contraction. Surviving myocytes slip past one another and elongate as the extracellular matrix remodels (Olivetti et al., 1990; Francis, 1998) . Cardiomyocyte dropout and slippage produce 'ventricular remodeling', resulting in an enlarged, thinwalled ventricle. These two factors, wall thinning and chamber dilation, strikingly increase the force that opposes ventricular contraction and blood ejection into the aorta. A mathematical description of this physical relationship was developed by the eighteenth century French physicist, Pierre Laplace, and reveals that wall stress (in the heart, afterload) is directly proportional to the radius of the chamber (r) and its intracavitary pressure (p), and is inversely proportional to the chamber wall thickness (h); stress ¼ pr/2h. Thus, any primary injury to the heart that causes cardiomyocyte dropout and ventricular remodeling produces a secondary stress on the heart in the form of increased afterload that is chronic and unremitting (Grossman et al., 1975) . Studies performed over the past decade have shown that this hemodynamic stress is a powerful stimulus for programmed cardiomyocyte death, initiating a vicious cycle of unfavorable geometrical remodeling that stimulates yet more cell death (Foo et al., 2005; Dorn II, 2009 ). The ultimate consequence, notwithstanding the nature of the inciting stimulus, is a downward functional spiral progressing to dilated cardiomyopathy and end-stage heart failure.
Cardiomyocyte apoptosis and BCL2 proteins in myocardial disease
The cycle of cardiomyocyte dropout and ventricular remodeling is chronic and persistent after a primary cardiac insult. This provides a therapeutic window of months to years to implement targeted interventions that can interrupt the cycle and prevent progression to end-stage heart disease. Furthermore, current understanding suggests that chronic cardiomyocyte dropout is overwhelmingly an active process mediated by distinct, but functionally redundant, cell signaling pathways that lead to different forms of programmed cardiomyocyte death (Figure 1 ). This rather complicated biology identified multiple potential therapeutic targets for preventing ventricular remodeling through inhibition of factors that cause programmed cardiomyocyte death. Apoptosis has been studied extensively in this regard.
Myocardium is intrinsically resistant to apoptosis, thought to be due at least in part to high levels of endogenous caspase inhibitors, such as X-linked inhibitor of apoptosis protein (XIAP) and apoptosis repressor with caspase recruitment domain (ARC) (Nam et al., 2004; Siu et al., 2005; Foo et al., 2007) . Thus, the rate of apoptosis in normal human heart is B1 per 10 000 cardiomyocytes, but apoptosis increases several hundred-fold in ischemic and dilated cardiomyopathy and reactive cardiac hypertrophy (Narula et al., 1996; Teiger et al., 1996; Olivetti et al., 1997) . Because adult cardiac myocytes are incapable of meaningful cellular regeneration (Rubart and Field, 2006) , chronic persistent apoptosis at a rate of 0.1-1% of total cardiomyocytes, as is observed in human cardiomyopathies, may be sufficient to produce cardiac dilation and heart failure (Hayakawa et al., 2003) . Cardiomyocyte apoptosis can be mediated either through cytokine death receptor pathways or the intrinsic, mitochondrial pathway. As the focus of this review is on two mediators of mitochondrial pathway apoptosis, BNIP3 and NIX/ BNIP3L, the interested reader is referred to other recent reviews of extrinsic apoptosis in the heart and elsewhere (Ashkenazi and Dixit, 1999; MacEwan, 2002; Danial and Korsmeyer, 2004) .
The key initiators, regulators and effectors of intrinsic pathway apoptosis are the BCL2 family of mitochondrial-targeted pro-and antiapoptotic proteins. Cardiac myocytes express a number of pro-and antiapoptotic BCL2 family proteins that are transcriptionally regulated in heart disease (Latif et al., 2000; Di Napoli et al., 2003) . Proapoptotic BCL2 proteins are classified according to structural features that reflect their different functions (Youle and Strasser, 2008) . The 'multidomain' proteins, BAX and BAK, are the essential pore-forming proteins that lead to mitochondrial outer membrane permeabilization, cytochrome c release and induction of the intrinsic apoptosis signaling cascade. The activity of these pore-forming proteins is enhanced by proapoptotic 'BH3 domain-only' proteins, like BNIP3 and NIX/ BNIP3L, and opposed by antiapoptotic factors like BCL2 and BCLX L that bind to and inhibit the BH3-only proteins. In the heart and elsewhere, the principal function of BH3-only proteins is to sense stress and initiate mitochondrial translocation of BAX or activation of mitochondrial localized BAK. Cardiomyocyte fate is therefore determined in part by regulated expression of these factors (Chen et al., 2001; Youle and Strasser, 2008 Figure 1 Transcriptional regulation of BNIP3 and NIX/BNIP3L. Separate pathways upregulate BNIP3 and NIX/BNIP3L in myocardial ischemia and hypertrophy, respectively, but they share a common apoptosis effector pathway. HIF-1a, hypoxia-inducible factor 1a; PKC, protein kinase C; Cyt c, cytochrome c.
conditions of stress. Yet, BAX expression increases and BCL2 expression decreases during chronic experimental cardiac pressure overloading (Condorelli et al., 1999) , NIX/BNIP3L is upregulated in human and experimental cardiac hypertrophy (Yussman et al., 2002; Galvez et al., 2006) , and BNIP3 expression increases in ischemic cardiac models (Regula et al., 2002; Galvez et al., 2006) . Recent data support a particularly important function for BNIP3 and NIX/BNIP3L in cardiomyocyte apoptosis during ventricular remodeling.
Stress-specific transcriptional control of cardiac BNIP3 and NIX/BNIP3L BNIP3 and NIX/BNIP3L are structurally similar products of separate genes and are cardiac expressed and transcriptionally regulated. Both of these BH3-only factors localize to and (by activating BAX and BAK) permeabilize mitochondrial outer membranes, which activates the intrinsic apoptosis signaling pathway (Chen et al., 1999) . Preventing mitochondrial localization of either BNIP3 or NIX/BNIP3L by mutational deletion of C-terminal mitochondrial targeting sequences creates dominant inhibitory proteins (Regula et al., 2002; Yussman et al., 2002) . Both proteins are also subject to rapid degradation by the ubiquitin-proteosome pathway (Chen et al., 1999; Cizeau et al., 2000) , accounting for barely detectable levels observed in the unstressed myocardium. Importantly, there appears to be no essential physiological or developmental function for either NIX/BNIP3L or BNIP3 in the heart, as cardiac structure and function are normal in the respective cardiac-specific and germ-line gene knockout mouse models (Diwan et al., 2007b (Diwan et al., , 2008b .
Because inappropriate expression of NIX/BNIP3L or BNIP3 is lethal to cardiac myocytes (see below), these death factors need to be tightly regulated. Indeed, both proteins are subject to strong negative repression under nonapoptotic conditions, but are selectively and robustly induced by stress signals. This feature underscores their importance as potential therapeutic targets, and considerable effort has been devoted to deciphering the signaling pathways and transcriptional control processes that govern basal and inducible NIX/BNIP3L and BNIP3 transcription. An important finding resulting from this work is that BNIP3 is uniquely induced in the heart by hypoxia, in contrast to other cardiacexpressed proapoptotic factors such as BAD, NIX/ BNIP3L, BAK and BAX (Regula et al., 2002; Yurkova et al., 2008) . NIX/BNIP3L may also be upregulated in an HIF-1a-dependent manner in some tissues (Bruick, 2000; Sowter et al., 2001; Birse-Archbold et al., 2005) , but NIX/BNIP3L gene expression is not induced by hypoxia/ischemia in the heart or in cultured cardiomyocytes. Because increased myocardial NIX/ BNIP3L mRNA levels were originally described in the heart in Gaq-mediated and pressure overload hypertrophy (Yussman et al., 2002) , signaling mechanisms within the Gq signaling pathway have been the focus for molecular studies of myocardial NIX/ BNIP3L regulation, and have revealed that protein kinase C (PKC)-mediated upregulation of transcription factor SP1 increases NIX/BNIP3L promoter activity in cardiomyocytes in vitro and in vivo (Galvez et al., 2006) .
Given their structural and functional similarities, the distinct transcriptional control pathways for NIX/ BNIP3L and BNIP3 are intriguing, and suggest that specific promoter elements are crucial for regulating NIX/BNIP3L or BNIP3 transcription by different stress signals. Sequence analysis of the proximal BNIP3 promoter uncovered a classical HIF-1 element and consensus sequences for the transcription factors nuclear factor-kB (NF-kB) and an E2F-1 (Baetz et al., 2005; Tracy et al., 2007; Yurkova et al., 2008) . BNIP3 gene expression in neonatal rat cardiac myocytes was transcriptionally silenced by constitutive binding of NF-kB to the BNIP3 promoter by recruitment of histone deacetylase-1 inhibitory complexes. Notably, the induction of BNIP3 gene expression during hypoxia coincided with a reduction in cellular NF-kB activity, and interventions that restored NF-kB BNIP3 promoter binding suppressed hypoxia-induced BNIP3 gene transcription. These findings highlight the importance of NF-kB in transcriptional control of BNIP3.
Recently, several groups have demonstrated that stress signals coupled to cell-cycle factor E2F-1 are sufficient to activate BNIP3 gene transcription during hypoxia (Tracy et al., 2007; Yurkova et al., 2008) . In gain-of-function studies, E2F-1 stimulated BNIP3 gene transcription, provoking mitochondrial defects and cell death in neonatal cardiomyocytes. Because genetic knockdown of E2F-1 or overexpression of a caspaseresistant Rb suppressed hypoxia-induced BNIP3 gene activation, the conclusion was that induction of BNIP3 promoter activity during hypoxia is contingent on E2F-1 (Yurkova et al., 2008) . In contrast, NIX/BNIP3L gene expression is unaltered in cardiac myocytes by NFkB, E2F-1 or hypoxia.
Because BNIP3 and NIX/BNIP3L are potent death factors, it follows that exquisite transcriptional control over factor genesis must be balanced by similarly tight control over factor activity and degradation. Indeed BCL2 and BCLX L interact with NIX/BNIP3L and BNIP3 (Chen et al., 1997; Yasuda et al., 1998; Ray et al., 2000) to antagonize apoptosis and/or autophagy. The growth factors epidermal growth factor and insulinlike growth factor appear to inhibit BNIP3-induced cell death in CHO and MCF7 cells (Kothari et al., 2003) . Work by the Webster laboratory indicated that acidosis during hypoxia enhances BNIP3-induced mitochondrial PTP opening and cell death, suggesting either that acidosis stabilizes BNIP3 protein, or that it can provide an as-yet undefined activating signal (Kubasiak et al., 2002; Frazier et al., 2006) . Ubiquitination and rapid proteasomal degradation of BNIP3 and NIX/BNIP3L was mentioned above (Chen et al., 1999; Cizeau et al., 2000) . Finally, the recent observation that BNIP3 can be reversibly phosphorylated may reveal another point of regulatory control (Graham et al., 2007) . As more complete details of tissue-and stress-specific pathways underlying the regulation of BNIP3 and NIX/BNIP3L are be defined, it is safe to say that the complexities delineated to date appear to reflect highly structured pathways that have evolved so that the heart can react to a variety of injuries or stressors by selectively 'finetuning' the disposition of damaged or injured cardiomyocytes.
Transgenic cardiac overexpression studies of BNIP3 and NIX/BNIP3L
Because endogenous cardiomyocyte BNIP3 and NIX/ BNIP3L are upregulated by myocardial stress or injury that can produce programmed cell death through other pathways, it was difficult to determine from simple association studies whether increased BNIP3 or NIX/ BNIP3L was sufficient to overcome the intrinsic apoptosis resistance of cardiomyocytes. To address this issue the Dorn laboratory used cardiomyocyte-specific promoters to transgenically overexpress both proteins in mouse hearts, and examined patterns of cardiomyocyte apoptosis in the absence and presence of myocardial stress.
NIX/BNIP3L was first overexpressed in mouse hearts using the standard a-myosin heavy chain (aMHC) transgene promoter (Yussman et al., 2002) . Two important characteristics of the aMHC expression system are that it is cardiomyocyte specific, and that measurable overexpression begins shortly after the birth of the mouse (Syed et al., 2004) . As a consequence, intrauterine cardiac development is not affected by aMHC-driven transgenes. aMHC-NIX/BNIP3L mice were born at expected Mendelian ratios, but their neonatal growth was stunted, and they succumbed after B1 week of life. Echocardiography performed on day 6 revealed left ventricular dilation and poor contractility, and histological studies of aMHC-NIX/BNIP3L hearts on days 6-7 revealed striking increases in the rates of cardiomyocyte apoptosis (15-20%). These findings were similar in two independent transgenic lines, demonstrating that increased NIX/BNIP3L expression is sufficient to cause a lethal apoptotic cardiomyopathy in neonatal mice. In a subsequent study where a conditional (tetracycline-suppressible) aMHC promoter was used to drive cardiomyocyte NIX/BNIP3L expression either from birth, or beginning in young adulthood, cardiomyocyte apoptosis was much more prevalent in neonates (B15%) than adults (B3%), and NIX/BNIP3L overexpression at even high levels in adults produced little effect on cardiac size or contractile function. However, when adult NIX/BNIP3L overexpression was superimposed on microsurgical creation of an aortic pressure gradient that in normal mice produces functionally compensated pressure overload hypertrophy, the result was left ventricular remodeling and progression to heart failure. These studies suggested that NIX/ BNIP3L is not only an initiator and effector of cardiomyocyte apoptosis, but is also a sensor of cardiac stress that helps to coordinate transcriptional and physiological cues for programmed cardiomyocyte death (Dorn II, 2005) .
A cellular mechanism for the putative stress-sensing function of NIX/BNIP3L was recently delineated, based on the observation that only B80% of transfected NIX/ BNIP3L localize to mitochondria in neonatal rat cardiomyocytes or HEK293 cells, with the remainder localizing to the endoplasmic reticulum/sarcoplasmic reticulum (ER/SR) (Diwan et al., 2008a) . These organelles are the predominant sites for intracellular calcium stores, and the highly organized subcellular architecture of adult cardiac myocytes enforces close proximity between SR and mitochondria, making it possible for calcium to transfer from SR to mitochondria through junctional microdomains referred to as 'calcium hot-spots' (Rizzuto and Pozzan, 2006) . Calcium delivery to mitochondria and uptake by the calcium uniporter are a potent stimulus for mitochondrial permeability transition (MPT) in the heart and elsewhere, and the resulting inner and outer membrane rupture leads to cell death from ATP depletion, called 'programmed necrosis' (Nakayama et al., 2007; Henriquez et al., 2008) . The Dorn group found that there is a direct relationship between NIX/BNIP3L level in NIX/BNIP3L-overexpressing and -knockout mice and SR calcium content, suggesting that ER/SRlocalized NIX/BNIP3L can affect intracellular calcium stores in a similar manner as previously reported for BCL2 and BAX (Foyouzi-Youssefi et al., 2000; Nutt et al., 2002; Scorrano et al., 2003) . To determine if ER/SR-localized NIX/BNIP3L contributed to programmed cell death, mitochondria-and ER/SR-specific mutants were engineered to compare their effects on cell viability, caspase activation and mitochondrial inner membrane potential (which is lost on opening of the permeability transition pore). Like wild-type NIX/ BNIP3L, both mitochondrial and ER/SR-specific NIX/BNIP3L caused programmed cell death associated with caspase activation. A NIX/BNIP3L mutant that remained in the cytosol did not produce cell death. Strikingly though, the mitochondrial localized NIX/ BNIP3L did not cause MPT, and resulting cell death was apoptotic (type 1 cell death), whereas the ER/SRlocalized NIX/BNIP3L caused mitochondrial depolarization and death from programmed necrosis (type 3 cell death). These findings demonstrate that NIX/BNIP3L mediates intrinsic pathway apoptosis though permeabilization of mitochondrial outer membranes and cytochrome release and so on. However, NIX/BNIP3L also causes programmed necrosis by localizing to ER/SR, where it increases calcium stores and therefore the mitochondrial delivery of calcium that causes the pore transition. In the context of recent studies identifying a role for NIX/BNIP3L (and probably BNIP3 as well (Hamacher-Brady et al., 2007; Kubli et al., 2008) ) in mitochondrial autophagy (Schweers et al., 2007; Sandoval et al., 2008) , these findings position NIX/BNIP3L at the apex of multiple parallel pathways leading to programmed cell death (Figure 2) .
Although the mechanistic studies for BNIP3 have not been performed at the same level of detail as with NIX/ BNIP3L, we believe that NIX/BNIP3L and BNIP3 have very similar cellular effects and the NIX/BNIP3L findings likely apply to BNIP3 under conditions where its expression is increased. The Dorn group has also examined the consequences of cardiomyocyte BNIP3 overexpression using a conditional cardiac expression system (Diwan et al., 2007b) . In contrast to NIX/ BNIP3L, BNIP3, expressed at a level approximately 50-times the normal (very low) level of basal myocardial expression, increased the basal rate of cardiomyocyte apoptosis only minimally (to B1%) after neonatal expression. However, mouse hearts in which BNIP3 overexpression was induced in adulthood developed markedly larger myocardial infarctions after microsurgical left anterior descending coronary artery occlusion (B35% of the left ventricle) than did their nontransgenic littermates (B20% of the left ventricle) (Diwan et al., 2007b) . These results indicate that increased BNIP3 expression can modestly increase cardiomyocyte apoptosis in normal hearts. More importantly, they also suggest that during ischemic stress, factors other than simple upregulation are important in generating the full apoptotic response to BNIP3 in ischemic injury. Whether this is hypoxia/acidosis-mediated post-translational modification and mitochondrial translocation of BNIP3 as has been suggested (Kubasiak et al., 2002; Kubli et al., 2008) , or some other as-yet unidentified factor such as nuclear translocation that is seen in ischemic brain injury (Schmidt-Kastner et al., 2004; Burton et al., 2005) , is not currently known.
Stimulus-specific interruption of myocardial apoptosis through targeted ablation of BNIP3 or NIX/BNIP3L BNIP3 and NIX/BNIP3L are transcriptionally upregulated in myocardium by different stimuli, but have similar effects on cardiomyocyte death, and thereby aggravate apoptotic cardiac remodeling. Accordingly, interrupting BNIP3-or NIX/BNIP3L-mediated programmed cell death in the heart might be able to prevent the adverse remodeling and heart failure that results from chronic cardiomyocyte dropout in ischemically damaged or hypertrophied hearts. The Dorn group examined this notion by creating the respective mouse gene knockout models, which were then subjected to a stimulus that would normally upregulate the ablated gene. Apoptosis, ventricular remodeling and cardiac performance were then compared over time in identically treated knockout and wild-type mouse hearts. For the BNIP3 germ-line knockout mouse (Diwan et al., 2007b) , a model of reversible left anterior descending coronary artery ligation that mimics early reperfusion after myocardial infarction was employed. As BNIP3 levels are barely detectable in normal, nonischemic myocardium, there is no real change in cardiac BNIP3 expression at baseline in mice lacking a functional BNIP3 gene. Consistent with this observation, BNIP3 ablation did not affect infarct size because these myocytes die shortly after interruption of blood flow, and before they can upregulate BNIP3 gene and protein expression. However, when post-ischemic apoptotic cardiomyocyte dropout was examined in the days after the acute ischemic insult (that is, after sufficient time for mechanisms that increase BNIP3 gene expression in ischemic tissue to be invoked), cardiomyocyte apoptosis was reduced by B50% in both the peri-infarct region and the myocardium remote from the ischemic zone of BNIP3 null mice. Decreased apoptosis in infarcted BNIP3 knockout hearts was associated with striking declines in left ventricular remodeling and improved cardiac performance, as measured by magnetic resonance imaging. Thus, prevention of BNIP3-mediated cardiomyocyte death during the days and weeks after a transient ischemic insult decreases apoptosis and prevents ventricular dilation, which preserved left ventricular ejection performance and abrogated heart failure. It should be noted that although apoptosis was the only form of programmed cell death specifically measured in these studies, the favorable effects of BNIP3 ablation on cardiomyocyte dropout and ventricular remodeling may also accrue from prevention of other forms of This pathway is inhibited in cardiac myocytes by high endogenous levels of the inhibitor of apoptosis proteins (XIAP) and apoptosis repressor with caspase recruitment domain (ARC). When pores in the mitochondrial outer membrane enlarge sufficiently, apoptosisinducing factor (AIF) and endonuclease-G (endo G) are also released and translocate to the nucleus to stimulate DNA degradation in a caspase-independent manner. Sarcoplasmic reticular (SR) NIX/BNIP3L, and possibly BNIP3, increases calcium transport to mitochondria, resulting in opening of the mitochondrial permeability transition pore (MPTP) that leads to necrotic cell death. NIX/BNIP3L and BNIP3 also target mitochondria for autophagic degradation, either directly through as-yet unknown mechanisms, or because of nonspecific consequences of MPTP-induced damage.
programmed cell death (autophagy, programmed necrosis) that may be mediated by BNIP3. There are several theoretical benefits to some form of anti-BNIP3 therapy after myocardial infarction or ischemia. First, the kinetics of BNIP3 upregulation after ischemia and the apparent chronic BNIP3-mediated cardiomyocyte dropout provide for a sizeable therapeutic window. Post-infarction ventricular remodeling occurs over the weeks and months following an acute ischemic event. This contrasts with the narrow therapeutic window of only 90 min after hospital presentation (or B6 h from infarction) for coronary reperfusion therapy to reduce myocardial necrosis and infarct size (Antman et al., 2008) . Second, anti-BNIP3 therapy might not necessarily need to be given specifically to the myocardium. The germ-line BNIP3 knockout mouse showed no detectable developmental or functional abnormalities in any organ system, including the hematopoietic system wherein increased numbers of lymphoid, myeloid and erythroid cells have been described for other BH3-only factor gene knockout models (Bouillet et al., 1999; Ranger et al., 2003; Diwan et al., 2007a) . This is consistent with the concept that BNIP3 functions almost exclusively in an inducible manner, and that ischemia is critical to increase its expression and possibly to activate it post-translationally (Kubasiak et al., 2002; Kubli et al., 2008) . Accordingly, systemic anti-BNIP3 therapy has the potential to prevent post-ischemic cardiac remodeling without untoward consequences in other tissues. Finally, the benefits of preventing programmed cell death during cardiac remodeling multiply by interrupting the vicious cycle of programmed cardiomyocyte death that increases myocardial stress by producing adverse geometrical changes, providing an additional and continuous stimulus for further programmed cell death. Possible approaches to inhibit BNIP3 include a cellpermeant (TAT-coupled) loss-of-function BNIP3 transmembrane domain deletion mutant that has been used in isolated perfused hearts (Hamacher-Brady A et al., 2007) or small molecules that could be designed to interfere with BNIP3 homo-and heterodimerization (Oltersdorf et al., 2005; Stauffer, 2007) .
Because it is upregulated in hypertrophy, it was postulated that inhibition of NIX/BNIP3L could prevent ventricular remodeling and the progression to heart failure in chronically pressure-overloaded hearts. We tested this notion using a similar strategy, microsurgical modeling of a NIX/BNIP3L knockout mouse. However, in contrast with BNIP3 where germ-line gene ablation showed no baseline phenotype, the germ-line NIX/ BNIP3L knockout mouse produced in the Dorn lab exhibited markedly increased blood reticulocyte counts associated with decreased in vivo and in vitro apoptosis of splenic erythroid precursers, and extreme hypersensitivity to erythropoietin (Diwan et al., 2007a) . A similar phenotype that included hemolytic anemia was subsequently described by two other groups who independently produced NIX/BNIP3L knockout mice (Schweers et al., 2007; Sandoval et al., 2008) . Because hematopoietic abnormalities such as these had the potential to confound cardiac studies, a Cre-lox strategy was used to create mice in which the NIX/BNIP3L gene was selectively ablated in cardiac myocytes, which were subjected to surgical transverse aortic constriction (TAC) (Diwan et al., 2008b ). This surgical model produces chronic pressure overload that can be modified to the needs of the particular experiment (mild, moderate or severe), and is therefore somewhat analogous to clinical hypertension or valvular aortic stenosis. As in these human conditions, mouse hearts subjected to TAC exhibit histological evidence of increased cardiomyocyte apoptosis that is associated with progressive ventricular dilation and, ultimately, functional decompensation. We observed that TAC in NIX/BNIP3L knockout mice produced only half the rate of early cardiomyocyte apoptosis and late replacement fibrosis as in control hearts, and that ventricular dilatation and wall thinning were largely prevented over the subsequent weeks, thus preserving systolic function. Importantly, both at the cellular level and in terms of whole organ weights, NIX/BNIP3L ablation did not change reactive left ventricular hypertrophy after pressure overloading. These data provided the first evidence that apoptosis is truly causal in decompensation of pressure overload, and establish NIX/BNIP3L as a critical inducible factor that mediates this response. Furthermore, the NIX/ BNIP3L and BNIP3 knockout remodeling rescue studies taken together prove that necrotic cardiomyocyte death is not the inevitable consequence of preventing the programmed death of ischemic or hypertrophied cardiomyocytes, as has been suggested (Foo et al., 2005) .
BNIP3 and NIX/BNIP3L in nonapoptotic programmed cell death
An underlying assumption of many of the studies reviewed above is that BNIP3 and NIX/BNIP3L kill cardiomyocytes through caspase-dependent apoptosis (type 1 cell death). However, it was recognized early on that BNIP3 can cause programmed cell death in a manner that does not require caspase activation and involve MPT (type 3 cell death). Our recent studies with organelle-specific NIX/BNIP3L mutants have more clearly defined a likely mechanism for NIX/BNIP3L-and BNIP3-mediated programmed necrosis via opening of mitochondrial permeability transition pores (MPTP, see above) (Diwan et al., 2008a) . Because MPTPmediated cardiomyocyte death appears to have a major function in various forms of heart injury associated with increased cytosolic or sarcoplasmic reticular calcium levels (Nakayama et al., 2007; Diwan et al., 2008a) , the mechanism is reviewed (see Figure 2) . Mitochondria are normally the major source of cellular ATP stores, which is needed to sustain the normal electrochemical gradient (Dc m ) across mitochondrial inner membranes. Calcium overload stimulates calcium-sensitive mitochondrial matrix dehydrogenases and impairs NADH production within the respiratory chain. Consequently, the inner mitochondrial membrane becomes more permeable to ions, resulting in loss of Dc m . This is the MPT (Haworth and Hunter, 1979) . The resulting oncotic influx of water structurally deforms and functionally impairs processes, such as ATP production, that occur within mitochondrial matrix. The mitochondria then become net consumers (rather than producers) of ATP, and the cell dies from suspension of minimal essential homeostatic functions (Leist et al., 1997) . MPT can be overlooked in studies of programmed cardiomyocyte death if it is not specifically assayed, as markers of apoptosis are invariably present because mitochondrial matrix swelling and disruption of the outer mitochondrial membrane releases the normally sequestered apoptotic effectors, cytochrome c, apoptosis-inducing factor (AIF) and endonuclease-G (EndoG) (Cregan et al., 2004; Saelens et al., 2004) . However, apoptosis may not be the cause of death in these cells, as the complex processes leading to apoptosis require ATP, and energy deprivation in cardiomyocytes undergoing MPT can interrupt apoptosis, thereby saving the cell from this particular form of programmed death. Such ATPdepleted cells that are not dead, but not really alive, have been called 'zombie myocytes' (Narula et al., 2001) . Nevertheless, the cardiomyocyte is likely to be doomed as the same ATP insufficiency that can prevent apoptosis also starves the calcium ATPases that pump calcium into the ER/SR. Unopposed calcium diffusion into the cytoplasm from ATP-deprived ER/SR produces even more calcium-mediated opening of MPTPs, ultimately resulting in cellular death from a cascade of programmed necrosis.
Given the link between mitochondrial function and cell survival, there is considerable interest in the involvement of mitochondrial perturbations induced by BNIP3 and autophagy. Autophagy is a cellular process for catabolism of intracellular proteins and organelles by lysosomal regulated pathways. The exact function of autophagy in programmed cell death is not fully understood (Kroemer and Levine, 2008) . It first and foremost represents an evolutionarily conserved survival pathway that includes a mechanism to selectively discard damaged or irreversibly injured organelles, particularly mitochondria (mitophagy) (Zhang et al., 2008) . Early removal of damaged mitochondria after injury could limit cell death by curtailing the mitochondrial regulated intrinsic death pathway.
The critical decision point and pathways that activate programmed cell death (apoptosis) versus nonapoptotic programmed autophagy are not currently known, but are likely coupled to the metabolic status of the cell by the mammalian target of rapamycin (mTOR). This notion is consistent with the activation of the mTOR pathway by positive growth signals and the concomitant inhibition of autophagy. In the context of the heart, autophagy has been demonstrated during hypoxia and ischemia-reperfusion injury and postulated to be mediated in part by BNIP3 (Hamacher-Brady et al., 2006; Tracy et al., 2007) . Interestingly, despite BNIP3's reported ability to provoke apoptosis during hypoxic or ischemic injury, in this study the autophagy by BNIP3 was suggested to be cytoprotective (Hamacher-Brady et al., 2006) . This was largely based on the finding that a dominant-negative mutant of Atg5 increased BNIP3-induced apoptosis, but reduced BNIP3-induced autophagy (Hamacher-Brady et al., 2007) . Further, in the same study, mitochondria were found in the autophagic vacuoles, leading the authors to conclude that the sequestration of damaged mitochondria may have protected hearts against ischemic injury.
Considering that BNIP3 can induce cell death in part through MPT (Regula et al., 2002) , which can induce autophagy (Lemasters et al., 1998) , one can envision a model wherein BNIP3 induces autophagy by activating early events required for permeability transition. Mitochondria that have undergone permeability transition pore opening would then be selectively removed from the cell by mito-autophagy, postponing or delaying induction of BNIP3-mediated apoptosis. Assuming a protective function for autophagy during ischemia reperfusion, one may speculate that during hypoxia or ischemia reperfusion, early activation of BNIP3-induced autophagy could actually protect against BNIP3-induced apoptosis. This is notion is consistent with the fact that deletion of the C-terminal transmembrane domain of BNIP3 (DTM) does not translocate to the mitochondria, induce permeability transition or affect autophagy or apoptosis in normoxic cells (Regula et al., 2002; Hamacher-Brady et al., 2007) . At present it is unknown whether BNIP3 directly activates autophagy or if autophagy is causally related to BNIP3-induced mitochondrial perturbations. A recent report found that Rheb (Ras-homologue enriched in brain), a key factor essential for mTOR activation, was inhibited by BNIP3 , linking BNIP3 to the mTOR pathway and further explaining how BNIP3 can induce apoptosis, necrosis and autophagy.
Summary
BNIP3 and NIX/BNIP3L are proximal regulators of multiple programmed cardiomyocyte death pathways. In the heart they are induced in a highly specific manner, and take weeks or longer to completely manifest their adverse effects on left ventricular remodeling. Specificity of induction and a prolonged period of action make them attractive targets for therapeutic interdiction. Furthermore, their positions at the apices of apoptotic, autophagic and programmed necrotic pathways suggest that their inhibition or ablation may prevent replacement of one form of cell death by another, as when AIFmediated cell death or autophagy substitutes for apoptosis after caspase inhibition. The potential benefits of this approach have been demonstrated by gene ablation in infarcted or pressure overloaded mouse hearts. However, translating to the human condition faces many challenges. If a pharmacological approach is to be used, then small molecular antagonists need to be developed that are sufficiently specific for BNIP3 and NIX/BNIP3L, and that do not produce untoward side effects in tissues (such as the hematopoietic system) that depend on their proapoptotic and/or autophagic actions to maintain normal cellular homeostasis. A gene therapy approach could have many advantages, as dominant inhibitory C-terminal truncated forms of both BNIP3 and NIX/BNIP3L have been introduced into the heart and have abrogated apoptosis and autophagy. However, although cardiomyocyte expression of truncated BNIP3 and NIX/BNIP3L may be an acceptable means to inhibit the parent endogenous factors, an optimal viral vector for cardiomyocyte gene therapy has not yet been described. Finally, it is interesting to speculate that inhibition of programmed cell death could find a role in myocardial stem cell therapy, as it is developed to regenerate damaged or dead myocardium. One of the hurdles of repopulating dead myocardium with cells that can differentiate into functional cardiac myocytes is that the stem or progenitor cells are necessarily introduced into a hostile tissue environment sufficiently unfavorable to have contributed to the loss of cardiomyocytes in the first place. Such a milieu provides many powerful stimuli for programmed cell death. Preventing apoptosis, autophagy and programmed necrosis might therefore enhance engraftment and increase the efficiency of stem-cell-mediated myocardial regeneration.
On the basis of the rapidity with which the field has advanced, the above possibilities seem tantalizingly within reach. However, even if the remaining challenges can be overcome, success in mice does not necessarily translate to man. HP Lovecraft appears especially prescient when he wrote in Herbert West: Reanimator (published in Home Brew in 1922):
West had already made himself notorious through his wild theories on the nature of death and the possibility of overcoming it artificially. His views, which were widely ridiculed by the faculty and by his fellow-students, hinged on the essentially mechanistic nature of life; and concerned means for operating the organic machinery of mankind by calculated chemical action after the failure of natural processes. In his experiments with various animating solutions, he had killed and treated immense numbers of rabbits, guinea-pigs, cats, dogs, and monkeys, till he had become the prime nuisance of the college. Several times he had actually obtained signs of life in animals supposedly dead; in many cases violent signs but he soon saw that the perfection of his process, if indeed possible, would necessarily involve a lifetime of research. It likewise became clear that, since the same solution never worked alike on different organic species, he would require human subjects for further and more specialized progress.
We trust that the outcome of current work will have a much more favorable impact than did that of the fictional Dr West.
